Abstracts tagged "Infection"

Abstract Number: 0981 • ACR Convergence 2021
Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims
David Singer¹, Philippe Thompson-Leduc², Sara Poston¹, Deepshekhar Gupta³, Wendy Cheng⁴, Siyu Ma¹, Francesca Devine⁵, Alexandra Enrique³, Mei Sheng Duh⁶ and Jeffrey Curtis⁷, ¹GlaxoSmithKline, Philadelphia, PA, ²Analysis Group, Inc., Montréal, QC, Canada, ³Analysis Group, Inc., Menlo Park, CA, ⁴Analysis Group, Inc., Boston, MA, ⁵Analysis Group, Inc., New York, NY, ⁶Analysis Group, Boston, MA, ⁷Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

Background/Purpose: Herpes zoster (HZ) is a disease caused by the reactivation of the varicella-zoster virus in previously infected individuals and is characterized by a painful…
Abstract Number: 1662 • ACR Convergence 2021
Unrecognised, Subclinical, Structural or Functional Lung Changes in Rheumatoid Arthritis Is Associated with a Higher Risk of Developing Serious Respiratory Tract Infection
Benjamin Worcester¹, Dorothy Wang², Susan Morton³ and Michelle Leech⁴, ¹Monash Health, Melbourne, Australia, ²Melbourne Health, Clayton, Australia, ³Monash Health, Clayton, Australia, ⁴Monash Medical Centre, Australia, Australia
Background/Purpose: The incidence of lung disease within the rheumatoid arthritis is well described and likely underestimated. Additionally, RA patients are at higher risk for developing…
Abstract Number: 0252 • ACR Convergence 2021
Role of Clinical and Laboratory Parameters in Differentiating Infection from Disease Flare in Febrile Patients of Systemic Juvenile Idiopathic Arthritis
Rajesh Kanumuri¹, Suma Balan², Vishal Marwaha², Sajitha Krishnan² and Pranav Chickermane², ¹Amrita Institute of Medical Sciences, Guntur, India, ²Amrita Institute of Medical Sciences, Kochi, India
Background/Purpose: Fever is the most common presentation of systemic juvenile idiopathic arthritis (SJIA) and it is difficult to predict whether the fever is due to…
Abstract Number: 0984 • ACR Convergence 2021
Human Papillomavirus Infection Increases Risk of Primary Sjogren’s Syndrome: A Population-based Cohort Study over a 15-year Follow-up
Kevin Sheng-Kai Ma, Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philidelphia, PA
Background/Purpose: Viral infection has been considered as an exogeneous risk factor for primary Sjogren’s syndrome (pSS). We determined whether human papillomavirus (HPV) infection was associated…
Abstract Number: 1684 • ACR Convergence 2021
Incidence of Infections in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Andra R Bălănescu¹, Gustavo Citera², Virginia Pascual-Ramos³, Carol A Connell⁴, David Gold⁵, All-shine Chen⁴, Harry Shi⁶, Andrea B Shapiro⁷, Janet Pope⁸ and Hendrik Schulze-Koops⁹, ¹“Carol Davila” University of Medicine and Pharmacy, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Montréal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Peapack, NJ, ⁸University of Western Ontario, London, ON, Canada, ⁹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany
Background/Purpose: Previous clinical trial and real-world data suggest that risk of serious infection events (SIEs) and opportunistic infections (OIs) is similar with tofacitinib 5 mg…
Abstract Number: 0337 • ACR Convergence 2021
Rarity of Pneumocystis Jirovecii Pneumonia in Patients with Systemic Lupus Erythematosus Using a Real-world, Electronic Health Record
Ben Boone and April Barnado, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Infection is the leading cause of mortality and one of the most common causes of hospitalization in patients with systemic lupus erythematosus (SLE). Pneumocystis…
Abstract Number: 1027 • ACR Convergence 2021
Epidemiology of Latent Tuberculosis Infection in Patients with Rheumatic Immune-mediated Diseases: Single University Study of 1117 Patients
David Martinez-Lopez¹, Joy Osorio-Chávez¹, Carmen Álvarez-Reguera¹, Virginia Portilla², Miguel Ángel gonzalez-Gay³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Background: Patients with rheumatologic immune-mediated diseases (R-IMID) with Latent tuberculosis infection (LTBI) requiring biologic therapy (BT) are at an increased risk of active tuberculosis…
Abstract Number: 1713 • ACR Convergence 2021
Risk of Serious Infections in Offspring Exposed in Utero to Ustekinumab or Vedolizumab
Jonah Gorodensky¹, Sasha Bernatsky¹, Waqqas Afif¹, Yvan St-Pierre², Kristian Filion¹ and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Ustekinumab, an IL-12/23 inhibitor, is indicated in adult patients with inflammatory bowel disease (IBD), psoriasis (PsO), and psoriatic arthritis (PsA) and vedolizumab, an α4β7…
Abstract Number: 0427 • ACR Convergence 2021
Increased Risk of Severe Infections and Mortality in Patients with Newly Diagnosed Anti-neutrophil Cytoplasmic Antibody–associated Vasculitis: A Population-based Study
Kai Zhao¹, Hui Xie², John Esdaile³ and J. Antonio Avina-Zubieta², ¹Simon Fraser University, Coquitlam, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) are a group of multisystem inflammatory diseases of the small blood vessels. Infections are serious complications in AAV…
Abstract Number: 1094 • ACR Convergence 2021
Extremely Elevated Erythrocyte Sedimentation Rate Revisited in Rheumatic Diseases: Flare-Up or Infection? Single Centre Retrospective Analysis
Emre Bilgin¹, Zehra Ozsoy², Melek Seren Aksun³, İmdat Eroğlu³ and Umut Kalyoncu¹, ¹Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Hacettepe University, Ankara, Turkey, ³Department of Internal Medicine, Hacettepe University, Ankara, Turkey
Background/Purpose: To compare the laboratory characteristics of patients who had rheumatic diseases and presented with extremely elevated ESR (≥100 mm/h) and had either disease flare-up…
Abstract Number: 1732 • ACR Convergence 2021
Effects of B Cell Activating Factors/B Lymphocyte Stimulator Inhibitors Added to Standard of Care on Infection in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Ruoning Ni¹, Jiayi Zheng² and Ruru Guo³, ¹Saint Agnes Healthcare, Baltimore, MD, ²Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (People's Republic), ³Renji Hospital, Shanghai, China (People's Republic)
Background/Purpose: The efficacy of B cell activator factor/B lymphocyte stimulator inhibitors (BAFFi/BLySi) for systemic lupus erythematosus (SLE) has been proven in clinical trials. However, it…
Abstract Number: 0429 • ACR Convergence 2021
Causes and Characteristics of Death in ANCA-Associated Vasculitis – A Large, Real-Life, Contemporary Cohort Analysis
Guy Katz¹, Claire Cook², Xiaoqing Fu¹, Hyon K. Choi³ and Zachary S. Wallace⁴, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA, ⁴Harvard Medical School, Boston, MA
Background/Purpose: Despite improvements, patients with ANCA-associated vasculitis (AAV) have a higher risk of death than the general population. Contemporary treatment is associated with high remission…
Abstract Number: 1288 • ACR Convergence 2021
First Year Infection Risk in SLE Patients Treated with Rituximab versus Standard of Care Treatment: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
Mia Rodziewicz¹, Sarah Dyball¹, Stephen McDonald¹, Emily Sutton¹, Ben Parker¹, The British Isles Lupus Assessment Group² and Ian N. Bruce¹, ¹University of Manchester, Manchester, United Kingdom, ²Lupus Trust, London
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) have an increased risk of infection compared to the general population. We aimed to assess the early risk…
Abstract Number: 1758 • ACR Convergence 2021
WITHDRAWN
Abstract Number: 0444 • ACR Convergence 2021
COVID-19 Vaccination in Autoimmune Disease (CoVAD) Study: Interim Analysis of Safety in Idiopathic Inflammatory Myopathies from a Large Multicentre Global Survey
Latika Gupta¹, James Lilleker², Vishwesh Agarwal³, Sinan Kardes⁴, Marcin Milchert⁵, Tamer Gheita⁶, Babur Salim⁷, Tsvetelina Velikova⁸, Oliver Distler⁹, Hector Chinoy¹⁰, Vikas Aggarwal¹ and Rohit Aggarwal¹¹, ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ²Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester, Centre for Musculoskeletal Research,, Manchester, United Kingdom, ³Mahatma Gandhi Mission Medical College, Navi Mumbai, India, ⁴Medical Ecology and Hydroclimatology Istanbul Faculty of Medicine, Istanbul, Turkey, ⁵Katedra Reumatologii i Chorób Wewnętrznych, Klinika Chorób Wewnętrznych Reumatologii Diabetologii Geriatrii i Immunologii Klinicznej PUM, ul. Unii Lubelskiej 1, 71-252 Szczecin,, Szczecin, Poland, ⁶Cairo University, Egypt, Cairo, Egypt, ⁷Fauji Foundation Hospital, Rawalpindi, Pakistan, ⁸University Hospital Lozenetz, Sofia, Bulgaria, ⁹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, ¹⁰University of Manchester, Salford, United Kingdom, ¹¹University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Numerous Covid-19 vaccines have demonstrated efficacy and safety against SARS-CoV-2 in general population. Despite favorable adverse effect (ADRs) profile of vaccines, there have been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].